Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients

被引:86
|
作者
Verburg, FA
de Keizer, B
Lips, CJM
Zelissen, PMJ
de Klerk, JMH
机构
[1] Univ Utrecht, Ctr Med, Dept Nucl Med, NL-3584 CX Utrecht, Netherlands
[2] Univ Utrecht, Ctr Med, Dept Endocrinol, NL-3584 CX Utrecht, Netherlands
关键词
D O I
10.1530/eje.1.01819
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Currently, little is known about the prognostic significance of achieving successful ablation with the first dosage of 1-131 in patients with differentiated thyroid cancer. This study aimed to assess the following: (i) whether successful or unsuccessful ablation at post-ablation follow-up has prognostic consequences; (ii) possible factors predicting success of ablation in a patient. Methods: In order to do this, we retrospectively studied 180 patients with a median follow-up of 55 months. Ablation was considered to be successful if I year after the initial dosage of 1-131 patients fulfilled all of the following criteria: not dead from thyroid cancer, no additional therapy needed for any kind for thyroid cancer within the first year, undetectable thyroglobulin (Tg) levels under TSH stimulation, and negative 1-131. scintigraphy. Tg levels at the time of ablation (P < 0.00.1.), lymph node metastasis (P = 0.04) and distant metastasis (P < 0.001.) have a significant influence on the success of ablation. P values were calculated by Mann-Whitney U test and Chi-square test, respectively. Results: Patients with successful ablation had a better prognosis than those with unsuccessful ablation: disease-free survival was 87%, versus 49% after 10 years; additionally, thyroid-cancer related survival was 93% versus 78%. Conclusion: We conclude that the extent of the remaining normal or neoplastic thyroid tissue influences the outcome of ablation, and that successful ablation leads to a better prognosis. It seems that it is very important to achieve complete ablation as soon as possible in order to ensure the best possible prognosis for a patient.
引用
收藏
页码:33 / 37
页数:5
相关论文
共 50 条
  • [31] Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine
    Giulliana Nóbrega
    Milena Cavalcanti
    Verônica Leite
    Lúcio Vilar
    Simone Cristina Soares Brandão
    Endocrine, 2022, 76 : 642 - 647
  • [32] Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine
    Nobrega, Giulliana
    Cavalcanti, Milena
    Leite, Veronica
    Vilar, Lucio
    Soares Brandao, Simone Cristina
    ENDOCRINE, 2022, 76 (03) : 642 - 647
  • [33] Reevaluating the Prognostic Significance of Age in Differentiated Thyroid Cancer
    Oyer, Samuel L.
    Smith, Valerie A.
    Lentsch, Eric J.
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2012, 147 (02) : 221 - 226
  • [34] Prognostic Significance of Thyroglobulin Antibodies in Differentiated Thyroid Cancer
    Reverter, Jordi L.
    Rosas-Allende, Irene
    Puig-Jove, Carlos
    Zafon, Carles
    Megia, Ana
    Castells, Ignasi
    Pizarro, Eduarda
    Puig-Domingo, Manel
    Granada, M. Luisa
    JOURNAL OF THYROID RESEARCH, 2020, 2020
  • [35] Thyroglobulin autoantibodies before radioiodine ablation predict differentiated thyroid cancer outcome
    Trimboli, Pierpaolo
    Zilioli, Valentina
    Imperiali, Mauro
    Giovanella, Luca
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2017, 55 (12) : 1995 - 2001
  • [36] Radioiodine Ablation for Differentiated Thyroid Cancer-None, One Dose or Two?
    Rees, G. J. G.
    CLINICAL ONCOLOGY, 2010, 22 (02) : 131 - 135
  • [37] Therapeutic efficacies of remnant ablation and radioiodine adjuvant therapy in differentiated thyroid cancer
    Liu, Yanlin
    Huang, Shuhui
    Li, Xiaohui
    Tian, Tian
    Huang, Rui
    ENDOCRINE, 2025, 87 (02) : 734 - 743
  • [38] Fractionated dosage of radioiodine for the ablation of differentiated thyroid carcinoma
    Czepczynski, R
    Ziemnicka, K
    Baczyk, M
    Oleksa, R
    Ruchala, M
    Sowinski, J
    THYROID, 2005, 15 (11) : 1261 - 1265
  • [39] Level VI Lymph Node Dissection Does Not Decrease Radioiodine Uptake in Patients Undergoing Radioiodine Ablation for Differentiated Thyroid Cancer
    Don Yoo
    Saad Ajmal
    Shilpa Gowda
    Jason Machan
    Jack Monchik
    Peter Mazzaglia
    World Journal of Surgery, 2012, 36 : 1255 - 1261
  • [40] Radioiodine refractory differentiated thyroid cancer
    Jin, Yuchen
    Van Nostrand, Douglas
    Cheng, Lingxiao
    Liu, Min
    Chen, Libo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 125 : 111 - 120